<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Silodosin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Silodosin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Silodosin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12203" href="/d/html/12203.html" rel="external">see "Silodosin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6813986"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rapaflo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869001"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AURO-Silodosin;</li>
<li>PMS-Silodosin;</li>
<li>Rapaflo [DSC];</li>
<li>Sandoz Silodosin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F6822374"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha <sub>1</sub> Blocker</li></ul></div>
<div class="block doa drugH1Div" id="F6822448"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ef9771-0186-450c-8cac-9fbc347a4341">Benign prostatic hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benign prostatic hyperplasia (monotherapy or combination therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients with moderate to severe predominant storage lower urinary tract symptoms, use in combination with beta-3 agonist or anticholinergic agent. In patients with a significantly enlarged prostate (prostate volume &gt;30 mL, prostate specific antigen &gt;1.5 ng/mL, or palpable prostate enlargement on digital rectal exam), use in combination with 5-alpha reductase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34384237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34384237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 8 mg once daily with a meal.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f22af56-3956-4591-9dca-11295dae391d">Ureteral stone(s) expulsion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ureteral stone(s) expulsion (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients with ureteral stones &gt;5 and ≤10 mm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-27908918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-27908918'])">Ref</a></span>). Although most evidence exists for distal ureteral stones, given the low side effect profile of alpha-blockers, may consider use in patients with stones in any location of ureter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616'])">Ref</a></span>). Additionally, may consider for use after shock wave lithotripsy to help pass stone fragments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27238616','lexi-content-ref-33179245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27238616','lexi-content-ref-33179245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 8 mg once daily with a meal until stone passage or for up to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620795','lexi-content-ref-25198942','lexi-content-ref-25530364','lexi-content-ref-27351320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620795','lexi-content-ref-25198942','lexi-content-ref-25530364','lexi-content-ref-27351320'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991547"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30-50 mL/minute: 4 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988671"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F6822449"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F6822384"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Genitourinary: Retrograde ejaculation (28%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (3%; increased in elderly ≥65 years up to 5%) </p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (3%), headache (2%), insomnia (1% to 2%) </p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%), abdominal pain (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Prostate specific antigen increased (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (2%), rhinorrhea (1% to 2%), sinusitis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hepatic insufficiency, hypersensitivity reaction, increased serum transaminases, intraoperative floppy iris syndrome, jaundice, pharyngeal edema, priapism, pruritus, purpura, skin rash (including toxic), swollen tongue, syncope, urticaria</p></div>
<div class="block coi drugH1Div" id="F6822380"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">US labeling: Hypersensitivity to silodosin or any component of the formulation, concurrent use with strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, ritonavir); severe renal impairment (CrCl &lt;30 mL/minute); severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent use with other alpha-blockers (eg, prazosin, terazosin, doxazosin).</p></div>
<div class="block war drugH1Div" id="F6822381"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension/syncope: May cause significant orthostatic hypotension with or without syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced although coadministration of sildenafil or tadalafil with silodosin was not associated with a clinically significant risk of orthostatic hypotension in one clinical trial (MacDiarmid 2010). “First-dose” orthostatic hypotension may occur 4 to 8 hours after dosing; may be dose related. Patients should be cautioned about performing hazardous tasks, driving, or operating heavy machinery when starting new therapy or adjusting dosage upward.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; contraindicated with severe impairment; not studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: It is recommended to rule out prostatic carcinoma before beginning therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate renal impairment; dosage adjustment recommended. Contraindicated in patients with severe impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• High potential for interactions: Contraindicated in patients on strong CYP3A4 inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; risk of orthostatic hypotension increases with increasing age. Patients ≥65 years of age experienced an incidence of up to 5% in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not indicated for use in children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antihypertensive use: Not intended for use as an antihypertensive drug.</p></div>
<div class="block foc drugH1Div" id="F6822456"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapaflo: 4 mg, 8 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block geq drugH1Div" id="F6822372"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16321883"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Rapaflo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $10.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $10.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Silodosin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $7.98 - $9.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $7.98 - $9.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869002"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapaflo: 4 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapaflo: 8 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block adm drugH1Div" id="F6822453"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with a meal. Capsules may be opened and the powder sprinkled onto a tablespoon of applesauce (not hot). The applesauce should be swallowed within 5 minutes without chewing and followed with 8 oz of cool water. Subdividing the capsule contents is not recommended. Do not store for future use.</p></div>
<div class="block use drugH1Div" id="F6822376"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Benign prostatic hyperplasia: </b>Treatment of signs and symptoms of benign prostatic hyperplasia.</p></div>
<div class="block off-label drugH1Div" id="F51196309"><span class="drugH1">Use: Off-Label: Adult</span><p>Ureteral stone(s)</p></div>
<div class="block mst drugH1Div" id="F6822370"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapaflo may be confused with Rapamune </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Silodosin may be confused with sildenafil, sirolimus</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9838536"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor), UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6840046"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Silodosin may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Silodosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Silodosin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Silodosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Alpha1-Blockers (Uroselective) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F6822423"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">AUC decrease by 4% to 49% and C<sub>max </sub>decreased by ~18% to 43% with moderate calorie/fat meal. Management: Take once daily with a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F58757491"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Silodosin may cause ejaculatory dysfunction, including anejaculation. Small studies conducted in healthy patients with normal semen parameters found anejaculation to be reversible when silodosin is discontinued. As a result, silodosin has been evaluated as an on-demand, reversible, nonhormonal, nonbarrier form of contraception (additional study needed) (Bearelly 2021; Bhat 2020; Kobayashi 2008).</p></div>
<div class="block pri drugH1Div" id="F6822378"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Silodosin is used off label for the treatment of ureteral calculi. Medical expulsive therapy has not been adequately studied in pregnant patients and is not recommended as initial therapy (AUA/ES [Assimos 2016]).</p></div>
<div class="block mop drugH1Div" id="F6822455"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">International Prostate Symptom Score (baseline and 4 to 12 weeks after treatment initiation); urinalysis (baseline); BP; objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021]).</p></div>
<div class="block pha drugH1Div" id="F6822426"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Silodosin is a selective antagonist of alpha<sub>1A</sub>-adrenoreceptors in the prostate and bladder. Smooth muscle tone in the prostate is mediated by alpha<sub>1A</sub>-adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha1-receptors in the prostate are of the alpha<sub>1A</sub> subtype.</p></div>
<div class="block phk drugH1Div" id="F6822428"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly absorbed (Lepor 2010)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 49.5 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive, via CYP3A4, glucuronidation, and alcohol and aldehyde dehydrogenase pathways; KMD-3213G (active <i>in vitro</i>) and KMD-3293 (not significant) metabolites formed</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~32%; bioavailability not altered if contents of capsule sprinkled on a tablespoonful of applesauce and administered</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy volunteers: Silodosin: ~13 hours (mean); KMD-3213G: ~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Silodosin: ~3 hours; KMD-3213G: ~5.5 hours (Lepor 2010)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (55%); urine (34%)</p></div>
<div class="block phksp drugH1Div" id="F51159893"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Total silodosin (bound and unbound) AUC, C<sub>max</sub>, and elimination half-life were 3.2-, 3.1-, and 2-fold higher, respectively, in patients with moderate renal impairment. Unbound AUC and C<sub>max</sub> were 2- and 1.5-fold higher, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Pharmacokinetics are not altered in patients with moderate hepatic impairment. Patients with severe hepatic impairment have not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Exposure and elimination half-life are approximately 15% and 20%, respectively, greater in subjects with a mean age of 69 years compared with subjects with a mean age of 24 years.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992808"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Flopadex | Silosin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Petrium | Siloflux</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Flowrap | Rapasin | Rapiflo | Siloflo</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Silodosin ab | Silodyx</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pirseo | Urorec</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">You li fu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fenanta | Silotrif</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Silodosin Recordati | Urorec</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Silodosin accord | Urorec</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Disorel | Silotrif | Teglinil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Silox</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sidarso | Urorec</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Congdosin | Eligodosin | Flopadex | Sildocare | Siloprostate | Sympaprost</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Silodosina aristo | Silodosina aurovitas | Silodosina cinfa | Silodosina krka | Silodosina mylan | Silodosina normon | Silodosina ratiopharm | Silodosina sandoz | Silodosina stada | Silodosina teva | Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Silodosine arrow | Silodosine biogaran | Silodosine eg | Silodosine mylan | Silodosine recordati | Silodosine sandoz | Silodosine teva | Silodosine zentiva | Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Urief</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Silodosin accord | Urorec</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alphacept | Lo dosin | Prostagard | Rapilif | Sidzox | Sildoease | Sildoo | Silodal | Silofast | Silorap | Silosmart | Silostride | Silotime | Silotrif | Siluri</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Silodosina aristo | Silodosina aurobindo | Silodosina doc | Silodosina eg | Silodosina krka | Silodosina mylan | Silodosina sandoz | Silodosina teva | Silodosina zentiva | Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Silofast | Silotrif | Urydos</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Furipass | Samsung silodosin | Sildosin | Silosin | Silurosin | Silverdosin | Thrupas | Unipass | Uridosin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Silosin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Silodosine biogaran | Silosin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Silodyx</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Silotrif</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Silodosine accord | Silodosine teva | Silodyx</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Silotrif</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Siloon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Silodosin aurovitas | Silodosin Recordati | Urorec</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rapaflo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Silodosina aristo | Silodosina Bluepharma | Silodosina Ciclum | Silodosina krka | Silodosina mylan | Silodosina ratiopharm | Silodosina teva | Silodyx | Urorec</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Silosin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sidarso | Silodosin stada | Urorec</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Urorec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Siliflo | Urief</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rapaflo | Rapflo | Silodyx | Silotrif</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Silotrif</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27238616">
<a name="27238616"></a>Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, PART I. <i>J Urol</i>. 2016;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/27238616/pubmed" id="27238616" target="_blank">27238616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31873859">
<a name="31873859"></a>Bayar G, Yavuz A, Cakmak S, et al. Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study. <i>Int Urol Nephrol</i>. 2020;52(5):835-840. doi:10.1007/s11255-019-02368-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/31873859/pubmed" id="31873859" target="_blank">31873859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34462095">
<a name="34462095"></a>Bearelly P, Avellino GJ. The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction. <i>Fertil Steril</i>. 2021;116(3):611-617. doi:10.1016/j.fertnstert.2021.07.1199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/34462095/pubmed" id="34462095" target="_blank">34462095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31076850">
<a name="31076850"></a>Bhat GS, Shastry A. A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: a pilot study. <i>World J Urol</i>. 2020;38(3):747-751. doi:10.1007/s00345-019-02806-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/31076850/pubmed" id="31076850" target="_blank">31076850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620795">
<a name="29620795"></a>Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. <i>Cochrane Database Syst Rev</i>. 2018;4(4):CD008509. doi:10.1002/14651858.CD008509.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/29620795/pubmed" id="29620795" target="_blank">29620795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15899440">
<a name="15899440"></a>Chang DF and Campbell JR, “Intraoperative Floppy Iris Syndrome Associated With Tamsulosin,” <i>J Cataract Refract Surg</i>, 2005, 31(4):664-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/15899440/pubmed" id="15899440" target="_blank">15899440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25198942">
<a name="25198942"></a>Dell'Atti L. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. <i>Urologia</i>. 2015;82(1):54-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/25198942/pubmed" id="25198942" target="_blank">25198942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27908918">
<a name="27908918"></a>Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. <i>BMJ</i>. 2016;355:i6112. doi:10.1136/bmj.i6112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/27908918/pubmed" id="27908918" target="_blank">27908918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18399947">
<a name="18399947"></a>Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. <i>J Sex Med</i>. 2008;5(9):2185-2190. doi:10.1111/j.1743-6109.2008.00779.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/18399947/pubmed" id="18399947" target="_blank">18399947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25530364">
<a name="25530364"></a>Kumar S, Jayant K, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). <i>Urology</i>. 2015;85(1):59-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/25530364/pubmed" id="25530364" target="_blank">25530364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21114397">
<a name="21114397"></a>Lepor H and Hill LA, "Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability,” <i>Pharmacotherapy</i>, 2010, 30(12):1303-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/21114397/pubmed" id="21114397" target="_blank">21114397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. <i>J Urol.</i> 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20080287">
<a name="20080287"></a>MacDiarmid SA, Hill LA, Volinn W, et al, “Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective Alpha 1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men,” <i>Urology</i>, 2010, 75(3):520-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/20080287/pubmed" id="20080287" target="_blank">20080287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33179245">
<a name="33179245"></a>Oestreich MC, Vernooij RW, Sathianathen NJ, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. <i>Cochrane Database Syst Rev</i>. 2020;11(11):CD013393. doi:10.1002/14651858.CD013393.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/33179245/pubmed" id="33179245" target="_blank">33179245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Preminger.1">
<a name="Preminger.1"></a>Preminger GM, Tiselius HG, Assimos DG, et al. 2007 guideline for the management of ureteral calculi. <i>J Urol</i>. 2007;178(6):2418-2434.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rapaflo.1">
<a name="Rapaflo.1"></a>Rapaflo (silodosin) [prescribing information]. Parsippany, NJ: Actavis; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RapafloCAN.1">
<a name="RapafloCAN.1"></a>Rapaflo (silodosin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma Co; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25465978">
<a name="25465978"></a>Sur RL, Shore N, L'Esperance J, et al. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. <i>Eur Urol</i>. 2015;67(5):959-964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/25465978/pubmed" id="25465978" target="_blank">25465978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27351320">
<a name="27351320"></a>Wang CJ, Tsai PC, Chang CH. Efficacy of silodosin in expulsive therapy for distal ureteral stones: a randomized double-blinded controlled trial. <i>Urol J</i>. 2016;13(3):2666-2671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/silodosin-drug-information/abstract-text/27351320/pubmed" id="27351320" target="_blank">27351320</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9520 Version 270.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
